öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÃ«ÐÂÁ¼
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º296

ËùÊôԺУ£º¹ãÖÝÖÐÒ½Ò©´óѧ
ËùÊôԺϵ£º301ÁÙ´²Ò©ÀíÑо¿Ëù
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼/²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º ÖÐÒ©·ÀÖÎÄÔ²¡µÄ×÷ÓûúÖÆÑо¿
Ñо¿ÁìÓò£º ÖÐÒ©·ÀÖÎÄÔ²¡µÄ×÷ÓûúÖÆÑо¿ [ÊÕÆð]




¸öÈ˼òÊö :
¸öÈ˼òÊö
1971Äê6Ô³öÉú£¬ºº×壬½ÌÊÚ£¬²©Ê¿ºóºÏ×÷µ¼Ê¦£¬²©Ê¿Ñо¿Éúµ¼Ê¦£¬Ë¶Ê¿Ñо¿Éúµ¼Ê¦¡£
Ö÷ÒªÈÙÓþ
½­ËÕÒ½Ò©¿Æ¼¼½Ü³öÇàÄê½±£¬½­ËÕÊ¡¡°333¸ß²ã´ÎÈ˲ÅÅàÑø¹¤³Ì¡±ÅàÑø¶ÔÏ󣬽­ËÕÊ¡¿Æ¼¼½ø²½Ò»µÈ½±

¿ÆÑй¤×÷ :
¹¤×÷¾­Àú
2000.06-2003.08¼ÓÄôóÂó¿ËÂí˹ÌØ´óѧ½øÐÞ²©Ê¿ºóÑо¿Ô±
2003.08-2004.08ÃÀ¹ú˹̹¸£´óѧ½øÐÞ²©Ê¿ºóÑо¿Ô±
2004.08-2006.05¼ÓÄôó¶àÂ׶à´óѧ½øÐÞ²©Ê¿ºóÑо¿Ô±
2006.05-2009.09¼ÓÄô󰲴óÂÔÊ¡Ö×ÁöÑо¿Ëù¹¤×÷ScientificAssociate
2009.09-ÖÁ½ñËÕÖÝ´óѧ¹¤×÷½ÌÊÚ¡¢²©µ¼¡¢ÏµÖ÷ÈÎ
2016.12¡ªÖÁ½ñ¹ãÖÝÖÐÒ½Ò©´óѧÁÙ´²Ò©ÀíÑо¿ËùÐÓÁÖ½²×ù½ÌÊÚ¡ª½ÌÊÚ¡¢²©/˶µ¼
ѧÊõ¼æÖ°
Ó¢¹úNature³ö°æÉçScientificReports±àί£¬½Ý¿Ë¹ú¼Ò¿Æѧ»ù½ðÆÀί£¬Ó¢¹úPharmacologica±àί£¬ºÉÀ¼CurrentPharmaceuticalDesign±àί£¬ÃÀ¹úAmericanJournalofTranslationalResearchÔÓÖ¾±àί£¬ÃÀ¹úAmericanJournalofBloodResearch±àί£¬ÃÀ¹úJournalofHematologicalMalignancies±àί£¬½­ËÕÊ¡Ò©Àíѧ»áÀíÊ£¬½­ËÕÒ©Î￪·¢ÓëÑо¿Ð­»áÀíÊ£¬ÖйúÒ©Àíѧ»áÉú»¯Óë·Ö×ÓÒ©ÀíѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬ÖйúÒ©Àíѧ»á¿¹Ñ×ÓëÃâÒßÒ©ÀíѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬ÃÀ¹úҩѧ»áÒéPharma2011×éί»áίԱ¡£
¿ÆÑÐÏîÄ¿
1¡¢¶à·¢ÐÔ¹ÇËèÁöϸ°ûÖдóMAF¼Ò×åµ°°×·ºËØ»¯Ã¸µÄµ°°××éѧ·ÖÎö¼°Æ䲡ÀíѧÒâÒåÑо¿£¬¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¨ÖØ´ó¹ú¼ÊºÏ×÷£©£¬280Íò£¬2014-2018£¬ÔÚÑУ¬Ö÷³Ö£»
2¡¢Ò»¸öÐÂÐÍPI3K°ÐÏòÖÎÁƶñÐÔ°×Ѫ²¡Ò©ÎïµÄÑÐÖÆ£¬½­ËÕÊ¡¿Æ¼¼Ìü(¿Æ¼¼Ö§³Å¼Æ»®)£¬45Íò£¬2014-2017£¬ÔÚÑУ¬Ö÷³Ö£»
3¡¢ÐÂÐÍPI3K°ÐÏòÖÎÁƶñÐÔ°×Ѫ²¡Ò©ÎïµÄÑÐÖÆ£¬ËÕÖÝÊпƼ¼¾ÖÖ§³Å¼Æ»®£¬2014-2017£¬ÔÚÑУ¬Ö÷³Ö£»
4¡¢à­ßøÀàÒ©Îï¶Ô¶à·¢ÐÔ¹ÇËèÁöµÄʵÑéÐÔÖÎÁÆ×÷Óü°ÆäÒÖÖÆ×éµ°°×È¥ÒÒõ£»¯Ã¸µÄ·Ö×Ó»úÀí¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¨ÃæÉÏÏîÄ¿£©£¬75Íò£¬2013-2016£¬ÒѽáÌ⣬Ö÷³Ö£»
5¡¢×ªÂ¼Òò×Óc-maf·ºËØÁ¬½ÓøcMULµÄ¼ø¶¨¼°ÆäÔڶ෢ÐÔ¹ÇËèÁö·¢Éú·¢Õ¹ºÍÖÎÁÆÖеÄÒâÒ壬¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¨ÃæÉÏÏîÄ¿£©£¬33Íò£¬2011-2013£¬ÒѽáÌ⣬Ö÷³Ö£»
6¡¢»ùÓÚÄÉÃײÄÁϵİ×Ѫ²¡²¡ÒòºÍ²¡ÀíѧÑо¿£¬¹ú¼ÒÖصã»ù´¡Ñо¿·¢Õ¹¼Æ»®£¨973¼Æ»®£©×Ó¿ÎÌ⣬×ܾ­·Ñ550Íò£¨¸öÈ˸ºÔð120Íò£©£¬2011-2015£¬ÒѽáÌ⣬Ö÷Òª¹Ç¸É£¨ÅÅÃûµÚ¶þ£©
7¡¢ÐÂÐÍPI3KÒÖÖƼÁPicromin¿¹ÑªÒºÖ×ÁöµÄ»úÀíÑо¿£¬½­ËÕÊ¡×ÔÈ»¿Æѧ»ù½ð£¨ÃæÉÏÏîÄ¿£©£¬10Íò£¬2010-2013£¬ÒѽáÌ⣬Ö÷³Ö£»
8¡¢¿¹ÒÖÓôÒ©°¢ÃÜÇúÌæÁÖÖÎÁƶ෢ÐÔ¹ÇËèÁöµÄÑÐÖÆ£¬ËÕÖÝÊпƼ¼¾Ö£¨Éç»áÖ§³Å¼Æ»®£©£¬15Íò£¬2010-2013£¬ÒѽáÌ⣬Ö÷³Ö£»
Ö÷ÒªÂÛÎÄ
[1]XuX,HanK,ZhuJ,MaoH,LinX,ZhangZ,CaoB,ZengY*,MaoX*.Aninhibitorofcholesterolabsorptiondisplaysanti-myelomaactivitybytargetingtheJAK2-STAT3signalingpathway.Oncotarget.2016Sep26.doi:10.18632/oncotarget.12265
[2]MaoH,WangM,CaoB,ZhouH,ZhangZ*,MaoX*.Interferon-stimulatedgene15inducescancercelldeathbysuppressingtheNF-¦ÊBsignalingpathway.Oncotarget.2016Sep21.doi:10.18632/oncotarget.12160.
[3]XuX#,HanK#,TangX,ZengY,LinX,ZhaoY,ZhangZ,CaoB,WuD,MaoX*.TheringfingerproteinRNF6inducesleukemiacellproliferationasadirecttargetofpre-B-cellleukemiahomeobox1.JBiolChem.2016Apr29291(18):9617-28.
[4]ZhangZ,TongJ,TangX,JuanJ,CaoB,HurrenR,ChenG,TaylorP,XuX,ShiC,DuJ,HouJ,WangG,WuD,StewartA,SchimmerA,MoranM,MaoX*.TheubiquitinligaseHERC4mediatesc-Mafubiquitinationanddelaysthegrowthofmultiplemyelomaxenograftsinnudemice.Blood,2016Mar31127(13):1676-86.
[5]ZhangZ#,MaoH#,DuX#,ZhuJ,XuY,WangS,XuX,JiP,YuY,CaoB,HanK,HouT,XuZ,KongY,JiangG,TangT,QiaoC,MaoX*.Anovelsmallmoleculeagentdisplayspotentanti-myelomaactivitybyinhibitingtheJAK2-STAT3signalingpathway.Oncotarget,2016Feb237(8):9296-308.
[6]JiP,XuX,MaS,FanJ,ZhouQ,MaoX*,QiaoC*.Novel2-Carbonylbenzo[b]thiophene1,1-DioxideDerivativesasPotentInhibitorsofSTAT3SignalingPathway.ACSMedChemLett.2015Jul276(9):1010-4.doi:10.1021/acsmedchemlett.5b00228.
[7]HanK,XuX,XuZ,ChenG,ZengY,ZhangZ,CaoB,KongY,TangX,MaoX*.SC06,anovelsmallmoleculecompound,displayspreclinicalactivityagainstmultiplemyelomabydisruptingthemTORsignalingpathway.SciRep.2015Sep25:12809.doi:10.1038/srep12809.
[8]JuanJ#,ChengL*,ShiM#,LiuZ,MaoX*.Poly-(allylaminehydrochloride)-coatedbutnotpoly(acrylicacid)-coatedupconversionnanoparticlesinduceautophagyandapoptosisinhumanbloodcancercells.JMaterChemB,20153:5769-5776.DOI:10.1039/c5tb00646e.
[9]ZhuJ,HouT*,MaoX*.Discoveryofselectivephosphatidylinositol3-kinaseinhibitorstotreathematologicalmalignancies.DrugDiscoveryToday.201520(8):988-94.doi:10.1016/j.drudis.2015.03.009.
[10]ZhuJ#,WangM#,YuY,QiH,HanK,TangJ,ZhangZ,ZengY,CaoB,QiaoC,ZhangH,HouT*,MaoX*.AnovelPI3KinhibitorPIK-C98displayspotentpreclinicalactivityagainstmultiplemyeloma.Oncotarget.2015Jan16(1):185-95.
[11]ShiM#,ChengL#,ZhangZ,LiuZ*,MaoX*.Ferroferricoxidenanoparticlesinducepro-survivalautophagyinhumanbloodcellsbymodulatingtheBeclin1/Bcl-2/VPS34complex.IntJNanomed.2014Dec2410:207-16.
[12]ChenG#,XuX#,TongJ,HanK,ZhangZ,TangJ,LiS,YangC,LiJ,CaoB,ZhouH,WuD,MoranMF,MaoX*.Ubiquitinationofthetranscriptionfactorc-mafismediatedbymultiplelysineresidues.IntJBiochemCellBiol.201457:157¨C166.
[13]CaoB,LiJ,ZhouX,JuanJ,HanK,ZhangZ,KongY,WangJ,MaoX*.Clioquinolinducespro-deathautophagyinleukemiaandmyelomacellsbydisruptingthemTORsignalingpathway.SciRep.20144:5749.doi:10.1038/srep05749.
[14]ZhuJ,WangM,CaoB,HouT*,MaoX*.Targetingthephosphatidylinositol3-Kinase/AKTPathwayforthetreatmentofmultiplemyeloma.CurrMedChem.201421(27):3173-87.
[15]TangJ#,ZhuJ#,YuY,ZhangZ,ChenG,ZhouX,QiaoC,HouT*,MaoX*.AvirtualscreenidentifiedC96asanovelinhibitorofphosphatidylinositol3-kinasethatdisplayspotentpreclinicalactivityinmultiplemyelomainvitroandinvivo.Oncotarget,20145(11):3836-48.
[16]ShiM#,ZhouX#,ZhangZ,WangM,ChenG,HanK,CaoB,LiuZ,MaoX*.AnovelPI3Kinhibitordisplayspotentpreclinicalactivityagainstanandrogen-independentandPTEN-deficientprostatecancermodelestablishedfromthecelllinePC3.ToxicolLett,**(3):133-9.
[17]LiJ#,ZhuJ#,CaoB,MaoX*.ThemTORsignalingpathwayisanemergingtherapeutictargetinmultiplemyeloma.CurrPharmDes.201420(1):125-35.
[18]HanK,XuX,ChenG,ZengY,ZhuJ,DuX,ZhangZ,CaoB,LiuZ,MaoX*.IdentificationofapromisingPI3Kinhibitorforthetreatmentofmultiplemyelomathroughthestructuraloptimization.JHematolOncol.20147(1):9.doi:10.1186/1756-8722-7-9.
[19]ChenG,HanK,XuX,DuX,ZhangZ,TangJ,ShiM,WangM,LiJ,CaoB,MaoX*.Ananti-leishmanialthiadiazineagentinducesmultiplemyelomacellapoptosisbysuppressingthenuclearfactorkappaBsignalingpathway.BritJCancer.**(1):63-70.
[20]CaoB,LiJ,ZhuJ,ShenM,HanK,ZhangZ,YuY,WangY,WuD,ChenS,SunA,TangX,ZhaoY,QiaoC,HouT,MaoX*.Theanti-parasiticclioquinolinducesapoptosisinleukemiaandmyelomacellsbyinhibitinghistonedeacetylaseactivity.JBiolChem.**(47):34181-9.
[21]LiJ#,CaoB#,ZhouS,ZhuJ,ZhangZ,HouJ,andMaoX*.Cyproheptadine-inducedmyelomacellapoptosisisassociatedwithinhibitionofthePI3K/AKTsignaling.EurJHematol.201391(6):514-21.(#contributedequally)
[22]ZhangZ#,DuX#,CaoB,ZhaoC,ZhaoY,MaoX*.Theanti-depressantamitriptylinedisplayspotenttherapeuticactivityagainstmultiplemyeloma.AnticancerDrugs.201324(8):792-8.(#contributedequally)
[23]ZhangZ,SongL,DongJ,GuoD,DuX,CaoB,ZhangY,GuN,MaoX*.Apromisingcombogenedeliverysystemdevelopedfrom(3-aminopropyl)triethoxysilane-modifiedironoxidenanoparticlesandcationicpolymers.JNanopartRes.201315(5),ArticleNo.1659.DOI:10.1007/s11051-013-1659-5.
[24]MaoX*.Targetingtheubiquitin-proteasomepathway-currentperspectivesandfuturedirections.CurrPharmDes.201319:3173-3174.
[25]CaoB,LiJ,MaoX*.Dissectingbortezomib:development,application,adverseeffectsandfuturedirection.CurrPharmDes.201319:3190-3200.
[26]LingC#,ChenG#,ChenG,ZhangZ,CaoB,HanK,YinJ,ChuA,ZhaoY,MaoX*.Adeuteratedanalogofdasatinibdisruptscellcycleprogressionanddisplaysanti-non-smallcelllungcanceractivityinvitroandinvivo.IntJCancer.**:2411-9.(#contributedequally)
[27]ZhuJ,LiY,YuH,ZhangL,MaoX*,HouT*.Insightintothestructuralrequirementsofnarlaprevir-typeinhibitorsofNS3/NS4AproteasebasedonHQSARandmolecularfieldanalyses.CombChemHighThroughputScreen.201215:439-50.

½ÌÓý±³¾° :
1989.09-1994.06»ªÖпƼ¼´óѧͬ¼ÃҽѧԺѧϰ»ñѧʿѧλ
1994.09-1997.06»ªÖпƼ¼´óѧͬ¼ÃҽѧԺѧϰ»ñ˶ʿѧλ
1997.09-2000.06±±¾©´óѧ¹«¹²ÎÀÉúѧԺѧϰ»ñ²©Ê¿Ñ§Î»
1998.10-1999.09ÈÕ±¾¸»É½Ò½¿ÆÒ©¿Æ´óѧѧϰ·ÃÎʲ©Ê¿Éú¡£